Navigation Links
Normal Bovine Serum from Equitech-Bio
Mouse Ameloblastin Biotinylated Affinity Purified PAb ENTREZ GeneID: 11698...
... to GRASP1 ( Abpromise for ... Antigen: Synthetic peptide corresponding to ... terminal region of rat GRASP1, conjugated ... Entrez GeneID: 56850 ...
Prepared from plasminogen by activation with immobilized human uPA...
Human VEGF R3/Flt-4 Phycoerythrin MAb (Clone 54733)...
Biology Products:
(Date:12/3/2009)... felt overly upset by a social snubbing? Your genetics, not ... known that opium-like painkillers, called opioids, relieve not only physical ... new study reviewed by Faculty of 1000 Biology member Markus ... the opioid receptor can determine the intensity of people,s responses ...
(Date:12/3/2009)... in Antarctic snowmelt that occurred during the 2008-09 austral ... for two main climate drivers, ENSO (El Nio - ... to Dr. Marco Tedesco, Assistant Professor of Earth & ... , Professor Tedesco, who is also on ...
(Date:12/2/2009)... PHILADELPHIA People who smoke their first cigarette within minutes ... by-product of nicotine when processed by the body, than those ... smoked. , "Since cotinine levels appear to ... smokers who smoke immediately after waking may be especially at ...
Breaking Biology News(10 mins):CCNY professor foresees rising Antarctic snowmelt 2Increased nicotine levels detected in those who light-up earlier 2When cells run out of fuel 9677 1When cells run out of fuel 9677 2Bioniche Phase III Clinical Trial with Urocidin 28TM 29 Given Continued Green Light by DMC 55122 1Bioniche Phase III Clinical Trial with Urocidin 28TM 29 Given Continued Green Light by DMC 55122 2Bioniche Phase III Clinical Trial with Urocidin 28TM 29 Given Continued Green Light by DMC 55122 3Swiffer Dusts Its Way Through Classrooms Across America 55120 1Swiffer Dusts Its Way Through Classrooms Across America 55120 2Swiffer Dusts Its Way Through Classrooms Across America 55120 3
... interested in receiving the full text of the press ... , Please note that all news releases are ... GENE SIGNATURE IDENTIFIES BREAST CANCER PATIENTS WHO WILL RESPOND ... have identified a genetic signature that can predict which ...
... 6, 2009 (BRONX, NY) Inappropriate use of ... of seizures in young children, according to a new ... of Yeshiva University. The study, published in this month,s ... educate communities about the hazards of camphor and to ...
... incident and the latest threats to shipping on the high ... 2009 IEEE International Conference on Technologies for Homeland Security (HST ... , Rear Admiral Richard Gurnon, USMS, president of the Massachusetts ... Monday 11 May at 8 a.m. , After graduating ...
Other Biology News:IMPAKT -- Breast cancer conference highlights 2Camphor-containing products may cause seizures in children 2
(Date:12/7/2009)... systems biology-driven therapeutics to include small molecules, chemotherapy and ... ... Cambridge, MA (PRWEB) December ... it has acquired Hermes Biosciences, Inc. a private biotechnology ... specializes in targeted drug delivery technologies for therapeutic and ...
(Date:12/7/2009)... 7 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: ... medical device research and,development outsourcing company with ... today it has purchased a Labcyte POD(TM) ... acoustic liquid handler for its work in ... PharmaTech joins the,growing number of pharmaceutical companies ...
(Date:12/6/2009)... Dec. 6 Boehringer Ingelheim today announced ... (150 mg BID), a direct thrombin inhibitor (DTI),(2) ... VTE. Results of the trial were presented ... Meeting and simultaneously published online in the ... Dabigatran etexilate met the primary outcome of the ...
(Date:12/4/2009)... Dec. 4 Vivakor, Inc. (OTC Bulletin Board: VIVK) ... 1, 2009 will receive the dividend of shares of ... by Vivakor,s Board of Directors. HealthAmerica is a ... of the outstanding common shares on the record date. ...
Breaking Biology Technology:Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 2Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 3WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Vivakor Confirms Record Date of Stock Dividend 2Vivakor Confirms Record Date of Stock Dividend 3